Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.

doi:10.1007/s10549-014-2980-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.

Breast cancer research and treatment - 1 Jun 2014

Sharma Priyanka, Klemp Jennifer R, Kimler Bruce F, Mahnken Jonathan D, Geier Larry J, Khan Qamar J, Elia Manana, Connor Carol S, McGinness Marilee K, Mammen Joshua M W, Wagner Jamie L, Ward Claire, Ranallo Lori, Knight Catherine J, Stecklein Shane R, Jensen Roy A, Fabian Carol J, Godwin Andrew K

Abstract excerpt

NCCN guidelines recommend genetic testing for all triple-negative breast cancer (TNBC) patients aged ≤60 years. However, due to the lack of prospective information in unselected patients, these guidelines are not uniformly adopted by clinicians and insurance carriers. The aim of this study was to determine the prevalence of BRCA mutations and evaluate the utility of NCCN guidelines in unselected TNBC population....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Genetic Testing

Share to Hereditary Breast and Ovarian Cancer Syndrome

Share to Ovarian Neoplasms

Share to Registries

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 24807107
DOI: 10.1007/s10549-014-2980-0
PMCID: PMC4171847

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.PMID 24807107Read ↗

Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.Semantic proximity Read ↗

Disparities in Hereditary Genetic Testing in Patients with Triple Negative Breast Cancer.Semantic proximity Read ↗

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.Semantic proximity Read ↗

Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.Semantic proximity Read ↗

Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.Semantic proximity Read ↗

Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.Semantic proximity Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.Semantic proximity Read ↗

Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?Semantic proximity Read ↗

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.Semantic proximity Read ↗

Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.Semantic proximity Read ↗

BRCA1/2 mutations and triple negative breast cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.